MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Macrogenics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors following significant stock price decline related to safety data misrepresentations of a drug [1][2]. Group 1: Legal Investigation - A class action complaint was filed against Macrogenics on July 26, 2024, with a class period from March 7, 2024, to May 9, 2024 [1]. - The investigation focuses on whether the board of directors of Macrogenics breached their fiduciary duties to the company [1]. Group 2: Stock Performance and Impact - During the class period, Macrogenics made material misrepresentations regarding the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine [2]. - Following the revelation that the drug was significantly more dangerous than previously stated, Macrogenics' stock declined by 77.4%, equating to a drop of $11.36 per share [2].